Rivaroxaban: Australian analysis for patients with AF compared with warfarin
Lancet Neurology, Volume 11, Issue 4, Pages 315 - 322, April 2012
In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). This study undertook a subgroup analysis to look at those patients with AF with an increased risk of stroke. They were randomised to receive either 20mg rivaroxaban daily or warfarin (to an INR of 2.0-3.0). The study aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA). Results support the use of rivaroxaban as an alternative to warfarin for prevention of recurrent as well as initial stroke in patients with AF.